Enrolling By Invitation PHASE2 INTERVENTIONAL 2-arm NCT05653310

Tradipitant for Functional Dyspepsia

Pharmacodynamics, Pharmacogenetics, Clinical Efficacy and Safety of Tradipitant for Functional Dyspepsia

Sponsor: Mayo Clinic

Updated 6 times since 2023 Last updated: Jan 16, 2026 Started: Feb 9, 2023 Primary completion: Jun 30, 2026 Completion: Jun 30, 2026

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT05653310, this PHASE2 trial focuses on Functional Dyspepsia and remains ongoing. Sponsored by Mayo Clinic, it has been updated 6 times since 2023, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Feb 2026 — Present [monthly]

Enrolling By Invitation PHASE2
May 2025 — Feb 2026 [monthly]

Enrolling By Invitation PHASE2
Sep 2024 — May 2025 [monthly]

Enrolling By Invitation PHASE2
Jul 2024 — Sep 2024 [monthly]

Enrolling By Invitation PHASE2
May 2024 — Jul 2024 [monthly]

Enrolling By Invitation PHASE2

Status: Not Yet Recruiting → Enrolling By Invitation

▶ Show 1 earlier version

Jan 2023 — May 2024 [monthly]

Not Yet Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Mayo Clinic
Xiao Jing (Iris) Wang

Data source: Mayo Clinic

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Rochester, United States